Celleron Therapeutics

SynOx Therapeutics Ltd, an Irish incorporated clinical stage biopharmaceutical company, has announced the closing of a €37 million Series A financing co-led by HealthCap and Medicxi and joined by investors Forbion and Gimv.

SynOx, a spin out of oncology company Celleron Therapeutics Ltd, secured exclusive world-wide rights for the clinical development, manufacturing and commercialisation of targeted antibody drug emactuzumab under a licence agreement with Roche.

Philip Lee was delighted to provide Irish law advice to Celleron on the spin out of SynOx and the Series A financing.

Further details available here.

Key Contacts

Key Contacts

News and insights

M&A Insights H1 2023 – A cross-border deal insight guide

M&A Insights H1 2023 – A cross-border deal insight guide

Key Contacts: Eoghan Doyle - Partner  |  Andrew Tzialli - Partner We are delighted to introduce the fifth edition of the Philip Lee M&A Insights guide. In this edition, we review deal activity across H1 2023, and consider the outlook for the rest of the year...

read more
The Web3 passport

The Web3 passport

Key Contacts: Andrew Tzialli - Partner  | Head of blockchain and crypto assets, Andrew Tzialli, spoke to the Web3 passport in their latest podcast to discuss the world of blockchain and digital assets. The Web3 passport podcast explores areas such as Web3, blockchain,...

read more
Share This